The National Institutes of Health Clinical Center (NIH CC) is the largest hospital in the United States devoted entirely to clinical research, with a highly diverse spectrum of patients. Patient safety and clinical quality are major goals of the hospital, and therapy is often complicated by multiple cotherapies and comorbidities. To this end, we implemented a pharmacogenomics program in 2 phases. In the first phase, we implemented genotyping for HLA-A and HLA-B gene variations with clinical decision support (CDS) for abacavir, carbamazepine, and allopurinol. In the second phase, we implemented genotyping for drug-metabolizing enzymes and transporters: SLCO1B1 for CDS of simvastatin and TPMT for CDS of mercaptopurine, azathioprine, and thioguanine. The purpose of this review is to describe the implementation process, which involves clinical, laboratory, informatics, and policy decisions pertinent to the NIH CC.
The National Institutes of Health Clinical Center (NIH CC) has 200 inpatient beds, 11 operating rooms, and 93 day-hospital wards. All patients at the CC consent to participate in research studies, are treated without charge, and must have a medical condition that is under study by an NIH institute or center to be eligible for treatment. There are currently more than 1600 clinical research studies under way led by approximately 500 principal investigators. These cover a wide range of illnesses: cancer, infectious diseases, blood disorders, heart disease, lung disease, alcoholism, and drug abuse. Of these protocols, 48% are intervention clinical trials (261 phase 1 trials, 462 phase 2 trials, 39 phase 3 trials, and 11 phase 4 trials). Over the years more than 500 000 patients have participated in clinical research at the NIH CC. Annually, 5600 patients are admitted to the NIH CC, 10 000 new patients are seen at the NIH, and approximately 100 000 outpatient visits occur. However, the NIH is not a full hospital conducting standard of care; therefore, new prescriptions are administered less often than those of other clinics. Because of the large and highly heterogeneous patient population seen at the NIH CC, often consisting of individuals with rare or orphan diseases, drug-disease and drug-drug interactions are of major concern and require careful management of medications in many cases. For this reason, we began the NIH CC effort to implement pharmacogenomics for clinical decision support (CDS) pertaining to certain medications. The purpose of this review is to highlight the clinical, laboratory, informatics, and policy procedures relevant to the implementation of germ-line pharmacogenomics testing for patients undergoing therapy at the NIH CC.
Gene-Drug Interactions With Clinical Guidelines
Generally, the NIH CC uses the recommendations of the Clinical Pharmacogenetics Implementation Consortium (CPIC), an international group of individuals from government, academia, and industry that peer-reviews and updates freely available clinical practice guidelines based on evidence-based methods (https://www.pharmgkb.org/view/dosingguidelines.do?source = CPIC). Currently, 36 medications from a wide variety of therapeutic classes have CPIC guidelines (see Table 1 ). The high representation of anticancer agents, antiinfectives, and antidepressants reflects the usefulness of pharmacogenomics when medications have a narrow therapeutic index with high risk of inefficacy and/or toxicity. 1 Many of these therapies are specifically associated with the risk of severe immune adverse reactions (iADRs; eg, carbamazepine, allopurinol, abacavir, etc.), which reflects the significance of that toxicity and the high predictive value of 4 distinct genotypes encoding certain human leukocyte antigens (HLAs), which are HLA-A*31:01, HLA-B*15:02, HLA-B*57:01, and HLA-B*57:02. 2 Genes with variants that result in a high degree of variation in the expression and function are highly represented in the CPIC guidelines. For instance, 12 of 36 of the CPIC guidelines relate to variation in CYP2D6, a gene that has numerous known functional polymorphisms and copy-number variations that affect its enzymatic turnover such that the metabolic phenotype ranges from poor to ultrarapid. 3 Many other genes represented in the CPIC guidelines have variants with high degrees of interindividual variation in phenotypes (see Table 1 ). The NIH CC effort to implement pharmacogenomics for clinical care has therefore focused on therapeutics that have severe side effects and highly predictive genotypes. Implementation is also guided by the existing information technology at the NIH CC. We chose to initially focus on gene-drug pairs in which knowledge of genotype or phenotype will improve drug therapy outcomes or reduce toxicity for those medications that are commonly initiated at the NIH CC. In addition, pharmacogenomic efforts are commonly incorporated into clinical research protocols as part of the research objectives. 
Pharmacogenetics Testing Implementation Committee and the Pharmacogenetics Subcommittee
For successful CDS design, 4 a multidisciplinary team is necessary to ensure a high-quality clinical framework and precise/accurate laboratory test methods. Therefore, the Pharmacogenetics Testing Implementation Committee (PGTIC) consisted of pharmacologists, pharmacists, nurses, informaticists, laboratory experts, and geneticists. The team was responsible for selecting the drug-gene pairs, designing the messages to prescribers, and constructing and testing the CDS algorithm. During implementation of the first phase, the PGTIC became the Pharmacogenetics (PG) Subcommittee of the Pharmacy and Therapeutics Committee (P&T Committee). The PG Subcommittee recommends the drug-gene pairs and the corresponding clinical recommendations to incorporate into the CDS. P&T Committee approval indicates that there is sufficient evidence that a preemptive assessment of the genotype and/or phenotype should be considered an integral part of clinical care. The NIH CC institutional process is diagramed in Figure 1 .
Technical Implementation
Ordering The NIH CC uses Allscripts Sunrise Clinical Manager 15.3 as the central component of the electronic health record, referred to as the Clinical Research Information System (CRIS). 5, 6 With guidance from the PG Subcommittee, a pharmacogenomics CDS program that is completely integrated into the natural medication order pathway was implemented within the electronic health record. 7 The current program is based on our previous experience with iADRs corresponding to abacavir, allopurinol, and carbamazepine therapies, as discussed in Goldspiel et al. 8 We have recently expanded this program to include genotyping drug-metabolizing and -transporting (DMET) genes, using the Affymetrix DMET Plus array that tests 1936 genetic variants in 235 pharmacogenes. There are 7 steps for processing the medication orders to incorporate CDS using the DMET platform that ultimately result in a clinical recommendation to the prescriber: Table 2 ). If no results are present, the Pharmacogenomics Multigene Test is preselected and available for submission.
An electronic order for the Pharmacogenomics
Multigene Test is made available to the external laboratory through a secured and encrypted fileshare process. 5. The external laboratory performs the test and provides a report in PDF and tab-delimited file Table 1 . This report is a sample and does not refer to an actual patient. formats containing the results of the test through a secured and encrypted file-share process. 6. The report is sent to CRIS in PDF format and is made available to users of the electronic health record. 7. Gene results specific to the CDS are stored in a table external to CRIS. The comprehensive report is stored in BTRIS, NIH's data repository. This report is provided to patients on request.
Genotyping
Following the order, whole-blood samples requiring HLA genotyping are sent to the Department of Transfusion Medicine (DTM), where HLA testing is conducted using HLA-A and HLA-B allele SEQR Typing Kits (Atria Genetics, Hayward, California) on a 3730xL DNA analyzer (Applied Biosystems, Carlsbad, California). 8 If the order requires typing of absorption, distribution, metabolism, and excretion (ADME) genes, whole-blood samples are sent to a core facility that conducts genotyping using the Affymetrix DMET Plus array in a CLIA-certified setting. The DMET array tests 1936 variants in 235 genes involved in absorption, distribution, metabolism, and/or elimination. This platform ascertains appropriate genotypes for the vast majority of gene-drug pairs covered by the CPIC guidelines. The DMET array also genotypes a multitude of other allelic variants that may be found useful as the landscape of pharmacogenomics testing expands.
Processing Results
We use a separate process to receive and store the genetics data generated by the laboratory. 7, 8 The laboratory providing the pharmacogenomic results places the PDF result and a tab-delimited file to a secured NIH share drive. A script runs every 5 minutes checking for the availability of the files and then completes the steps below:
1. The script parses the order identifier and patient identifier from the filename of the PDF. (1) Table 2 . This report is a sample and does not refer to an actual patient. (Continued)
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The Journal of Clinical Pharmacology / Vol 57 No S10 2017 file and sends it to the CRIS electronic health record via an HL7 result message. The PDF is stored on a Clinical PDF File Server, whereas a link is stored in the CRIS electronic health record pointing to this PDF file. An example of the PDF Report is shown in Figure 3 and As part of the quality assurance process, on order entry, an email notification is also sent to 2 members of the PG Subcommittee to monitor the process. On results being received by CRIS, the pharmacy PG Subcommittee member and the provider entering the medication order receive an email that results are within CRIS for the Pharmacogenomics Multigene order. An identification number within the email message allows the user to log in to CRIS and retrieve the results for the patient. The prescriber can then proceed to ordering the medication if appropriate.
Education
Implementation of the pharmacogenomics CDS program affects all members of the health care team: clinicians, pharmacists, nurses, laboratory medicine staff, and patients. The pharmacy department therefore initiated an education program for hospital staff that included information pertaining to pharmacogenomics guidelines, the availability of the laboratory test, and the order entry process. To reach all clinicians, a variety of methods were used including Clinical Alert flyers, in-service training programs, and email communication to targeted clinicians. In addition, warning messages, instructions, labels, and information for the medication and genomic tests are provided to prescribers (see Table 3 ). In-service training programs are also provided S75 to pharmacy, nursing, and laboratory staff as part of the initial implementation.
As part of the continuous learning program, nurses also developed a Genetics and Genomics in Healthcare course and competency to provide nursing with a broader understanding of how genomics interplays with patient care and medication administration. The Genetics and Genomics course is available to all health care providers within the NIH and has 2 sectionsIntroduction and Intermediate. The Introduction course, a 1-day course, is required of all nursing staff, who must complete a competency requirement. The Intermediate course is a 2-day program (syllabus included in Figure S1 ).
Educational materials were created for the patient ( Figure S2 ). This information is available in the medical order in the electronic health record to allow clinicians ready access to a document for use in discussion with the patient. It is also available on the internal access page of the pharmacy department. As more gene-drug pairs are introduced at NIH, educational information will be provided/presented to staff to appropriately care for patients. Educational materials will be developed on the new drugs for patients and will be available through current processes.
Current Status of Implementation
The clinical pharmacogenomics program was implemented in 2 phases. The first phase included drug-gene pairs in which HLA variations were ascertained for prediction of potential dermatologic reactions following abacavir (HLA-B*57:01), allopurinol (HLA-B*58:01), and carbamazepine (HLA-A*31:01 and HLA-B*15:02) treatment. 8 The second phase included genetic variants in ADME genes that are associated with the dose or toxicity of a medication.
HLA genotyping was implemented first because the DTM had already developed assays for the highresolution HLA gene sequencing, and such therapies are frequently ordered at our institution. Therefore, implementation only involved controlling the test name to trigger the CDS and was used by prescribing physicians shortly thereafter. The results to date are similar to our previous conclusions 8 : prescribers order the gene test frequently because of the construct of the order form. A CDS algorithm was recently approved for genotyping HLA-B*15:02 prior to phenytoin therapy; however, we have not yet implemented this algorithm.
DMET testing involves ascertaining genotypes of 235 different pharmacogenes and determining the genotype-predicted phenotype of a subset of these genes. Therefore, implementing the second phase was more challenging because it involved both the development of a CLIA-certified Affymetrix DMET-Plus array test and the ability to securely and automatically transmit the results for use in CDS. We have algorithms approved for genotyping several gene-drug pairs: solute carrier organic anion transporter family member 1B1 (SLCO1B1) and simvastatin; thiopurine methyltransferase (TPMT) and azathioprine, mercaptopurine, and thioguanine; CYP2C9 and phenytoin (implementation is pending). 9 Initially, we reported all phenotypes that were determined by the Affymetrix software. Only the approved drug-gene pairs are programmed for CDS. The additional phenotypes could be used by the clinician if they believed that the information could contribute to better medication therapy. Although we had completed testing on the algorithms, we soon discovered that the phenotype report produced multiple phenotype results when a single genotype could not be determined. This is a result of the software making all possible calls when a single call cannot be made. We then decided to have human interpretation for the 3 approved druggene pairs and report just the software-generated genotypes for the other genes on the chip. This unexpected result has reduced our ability to provide comprehensive preemptive testing and will require us to backfill reports as new drug-gene pairs are approved. We have since updated all the patient results in the system.
Models at Other Institutions
Many institutions have integrated genotyping for pharmacogenomics testing into standard clinical care programs. 10 Heterogeneity exists among several aspects of how these programs are structured and implemented. First, some institutions concentrate these initiatives in specialized clinics or pharmacogenomics consult services. In contrast, the NIH CC model is one in which testing is intended to be available to all clinicians; therefore, results and recommendations are relayed to clinicians in the form of CDS imbedded in the electronic health record. Second, institutions vary greatly in which drug-gene pairs are included in these initiatives and which regulatory bodies are required for approval. The most common structure is creation of a pharmacogenomics subcommittee of the P&T Committee to evaluate the evidence and present recommendations prior to approval by the P&T. Alternatively, some institutions rely on consensus from external guidelines and/or internal consensus among clinicians using affected drugs in their services, for example, the University of North Carolina Chapel Hill Inpatient Cardiology Service program for clopidigrel/CYP2C19 testing. 7 Efforts to standardize approaches to evaluate evidence in literature and incorporating pharmacogenomics results into clinical guidance are being provided by organizations, such as the Clinical Pharmacogenetics Implementation Consortium and the Pharmacogenomics Knowledgebase. Both organizations use an evidence-based, tiered system of grading pharmacogenetic associations. 11 Perhaps the largest difference in institutional use of pharmacogenomics testing for clinical care involves the use of preemptive or reactive testing. A majority of initiatives are currently designed for reactive testing, in which pharmacogenomics testing is ordered at the time of ordering a drug for which an approved drug-gene pair has been established at the institution. For this model to be successful, however, the turnaround time for results is a crucial component. St. Jude Children's Research Hospital's PG4KDS Protocol is currently the largest program to offer preemptive pharmacogenomics testing to all patients treated at the institution; more than 3000 patients were preemptively genotyped. Although this is a highly unique and specialized institution, other institutions with broader patient populations, such as the Mayo Clinic, have also successfully piloted large-scale preemptive pharmacogenomics testing programs. Such programs highlight the potential for the successful transition from reactive testing to preemptive pharmacogenomics testing as the standard of care. 12 The preemptive testing approach offers the opportunity for clinician researchers to access all single-nucleotide polymorphism array test results for exploratory analyses of new pharmacogenomic associations and for future clinical utility.
Each institution must determine the approach that will allow for ease of use and long-term sustainability of the pharmacogenomics program. Ultimately, no matter which approach is selected, the priority should be focused on ensuring the institution is providing actionable data to health care practitioners and easyaccess utilization of these data in their practice, thus achieving the end goal of providing precision medicine.
Discussion
The current NIH CC pharmacogenomics testing approach is designed to minimize adverse drug reactions and maximize therapeutic efficacy by preemptively informing the selection of therapy at the right dose. The strategy we have employed is expected to cover all CPIC guidelines irrespective of race within the next 5 years and is adaptable to the changing landscape of the pharmacogenomics literature. Moreover, we have designed the program to allow multiple NIH physicians and clinics to access genomic data from a central source, the electronic health record. We also provide patients with their genotype data so that local physicians can use the information when patients return to their local community. However, as the NIH is solely a research hospital, our pharmacogenomics effort has been implemented more slowly and on a smaller scale than at many other institutions.
Broad clinical pharmacogenomics implementation in hospitals is a rather recent event, with widely accepted clinical guidelines for important gene-drug interactions only occurring in the past 6 years. 13, 14 These guidelines are useful for standardizing CDS across multiple hospitals. However, decisions such as the regulatory framework to implement CDS, which testing platforms to use, how to include CDS data in the medical record, and physician/patient education programs involve decisions that depend on factors specific to individual hospitals. The NIH CC has implemented the above guidelines because we service a large, diverse, highly specialized, and multidisciplinary institution with more than 1600 clinical studies, involving patients with severe and complex disorders on short-term but intensive care regimens.
Because the NIH CC already had CDS support for HLA-A and HLA-B haplotypes in place, we chose to implement testing prior to abacavir, allopurinol, and carbamazepine medication first and added other tests in a second phase once we developed CLIA support for the DMET array. The DMET array was chosen because multiple variants in many genes that are not currently ascertained in the CPIC guidelines are included, and we have banked these "extra" data in case additional variants are needed in the future. Our choice of genedrug pairs to implement first in the second phase depended on the prevalent use of these drugs in many clinics throughout the NIH CC (ie, simvastatin and phenytoin) or the highly predictive value of genotyping patients receiving mercaptopurine and its analogues. Therapies that are guided by somatic mutations are implemented by the NIH pathology department and are therefore beyond the scope of this review. 15 The implementation has involved several challenges that have warranted a slower implementation process at the NIH CC for a variety of reasons. First, the NIH CC is a pure research hospital, and clinical protocols are very often written to provide the necessary pharmacogenomics coverage when applicable to experimental therapies. Second, as a pure research hospital, the NIH is not providing standard of care. Most patients who are referred to the NIH are already taking prescribed medications with pharmacogenomics indications at local clinics and require preemptive genotyping much more rarely than patients in other hospitals. We have also developed a mechanism to transmit pharmacogenomics information back to the local physician, which has also been challenging. Next, the NIH is very large and highly multidisciplinary; this aspect of the NIH CC requires careful implementation and broad communication between the PGTIC and various clinics on the NIH campus. Such communication has been a necessary component of implementation because many clinics have developed local methods to determine which alleles require genotyping before therapy. The PGTIC has therefore partnered with clinics that frequently use pharmacogenetics testing to add value to existing CDS infrastructure while still providing a central CDS resource that is available to all NIH physicians. Fourth, despite careful quality control, the DMET array does not always return all 1936 genotypes that are probed, and therefore we have had to develop means to determine whether DMET testing can still provide actionable information in such contingencies. Finally, we have intentionally introduced implementation in a stepwise fashion so that CDS can be "betatested" without introducing undue burden on NIH research and patient care. Future efforts will focus on introducing additional gene-drug pairs into clinical implementation and increasing the adaptability of the pharmacogenomics program as new studies are published on genes that we have currently not ascertained a genotype.
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